AUTHOR=Luo Xiaodan , Chen Ao , Qin Le , Weinkove Robert , Zhao Rong , Ye Ting , Chen Sihui , Tang Jianli , Liu Jianbo , Huang Jiayu , Shi Boyun , Yuan Danyun , Tan Huo , Qin Dajiang , Tang Zhaoyang , Li Peng , Zheng Runhui 

TITLE=Case report: A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma

JOURNAL=Frontiers in Immunology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1497736

DOI=10.3389/fimmu.2024.1497736

ISSN=1664-3224

ABSTRACT=This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3ζ signaling domains, along with a TLR2 costimulatory domain. This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications. This case suggests that combining myeloablative ASCT with tandem anti-CD19/CD22 CAR T cell therapy could be an effective approach for R/R BL, warranting further clinical validation.